Quick Search
Advanced Search
Number Search
Last Results list
My patents list
Classification Search
Get assistance

Quick Help
- Why are some data unavailable for certain documents?
- How does a list of documents with the heading "Also published as" sometimes appear, and what do these documents?
- What does A1, A2, A3 and B stand for after an EP publication number in the "Also published as" list?
- What is a cited document?
- How do I sometimes find the abstract of a corresponding document?
- What is a mosaic?

Condensed diazepinones, process for their preparation, and medicaments containing these compounds.

Patent number: EP0417631
Publication date: 1991-03-20
Inventor: ENGEL WOLFHARD DR DIPL-CHEM (DE); EBERLEIN WOLFGANG DR DIPL-CHEM (DE); TRUMMLITZ GUENTER DR DIPL-CHEM (DE); MIHM GERHARD DR DIPL-CHEM (DE); DOOOS HENRI DR (DE); MAYER NORBERT DR (DE); DE JONGE ADRIAAN DR (NL)
Applicant: THOMAE GMBH DR K (DE)
Classification:
- international: *C07D487/10; C07D519/00;* C07D487/00; C07D519/00; (IPC1-7): A61K31/55; C07D487/10; C07D519/00
- european: C07D487/10; C07D519/00
Application number: EP19900117078 19900905
Priority number(s): DE19893930262 19890911

View INPADOC patent family

Also published as:
- JP3209382 (A)
- EP0417631 (A3)
- DE3930262 (A1)
- DD298308 (A5)
- RU2017740 (C1)

more >>

Cited documents:
- US4210648
- US4424225
- US4424226
- DE3726908
- EP0106459

Report a data error here

Abstract of EP0417631

Condensed diazepinones of the general formula I in which is one of the divalent radicals K is a =CH group or a nitrogen atom, R is a lower alkyl radical which can optionally also be substituted by a phenyl which optionally carries halogen, methyl or methoxy, R<4> and R<5> are hydrogen, halogen or lower alkyl, R<6> is hydrogen, chlorine or methyl, R<7> and R<8> are lower alkyl, R<8> is additionally also halogen, and m, n, o and p are the numbers 1 or 2, where the total of m + n + o + p must be equal to or less than 5, are suitable for the therapy of cholinergically related spasms and motility disturbances in the gastrointestinal tract, in the biliary tract, for the symptomatic therapy of cystitis and of spasms associated with urolithiasis, for the therapy of relative incontinence, for the symptomatic therapy of bronchial asthma and of bronchitis, and for the therapy of ischaemic heart diseases. The compounds are distinguished by high selectivity.

Data supplied from the *esp@cenet* database - Worldwide